Inozyme Pharma News

Needham: Reiterates Inozyme Pharma (INZY.US) rating and adjusted from buy to buy rating, target price of $23.00.

Zhitong FinanceApr 9 20:02

Inozyme Pharma Analyst Ratings

BenzingaApr 9 19:53

Analysts' Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Zai Lab (ZLAB) and Idexx Laboratories (IDXX)

TipRanksApr 9 18:20

Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX), Inozyme Pharma (INZY) and PTC Therapeutics (PTCT)

TipRanksApr 9 17:40

HC Wainwright & Co. Maintains Buy on Inozyme Pharma, Maintains $16 Price Target

BenzingaMar 13 21:29

Buy Rating for Inozyme Pharma Backed by Promising Clinical Progress and Unique Market Positioning of INZ-701

TipRanksMar 13 18:16

Inozyme Pharma: Strong Buy Rating Amidst Promising Trial Developments and Market Underappreciation

TipRanksMar 13 00:45

Inozyme Pharma Analyst Ratings

BenzingaMar 13 00:34

Inozyme Pharma Analyst Ratings

BenzingaJan 30 23:49

Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target

BenzingaNov 8, 2023 17:52

Inozyme Pharma Analyst Ratings

BenzingaNov 8, 2023 17:51

TD Cowen Reaffirms Their Buy Rating on Inozyme Pharma (INZY)

TipRanksNov 8, 2023 05:26

Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target

BenzingaSep 27, 2023 18:31

Inozyme Pharma Analyst Ratings

BenzingaSep 27, 2023 18:30

Analysts' Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Ionis Pharmaceuticals (IONS) and Cano Health (CANO)

TipRanksSep 27, 2023 09:10

Positive Clinical Trial Updates Boost Inozyme Pharma's Buy Rating: Efficacy of INZ-701 in ENNP1 and ABCC6 Deficiencies

TipRanksSep 27, 2023 09:10

Promising Trial Results and Financial Stability Bolster Buy Rating for Inozyme Pharma's Stock (INZY)

TipRanksSep 27, 2023 00:25

Wedbush Maintains Outperform on Inozyme Pharma, Announces $15 Price Target

BenzingaSep 8, 2023 23:00

Inozyme Pharma Analyst Ratings

BenzingaSep 8, 2023 22:59

Inozyme Pharma Analyst Ratings

BenzingaAug 9, 2023 16:09